Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
73 hedge funds and large institutions have $639M invested in Apellis Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 33 increasing their positions, 4 reducing their positions, and 8 closing their positions.
725% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 4
313% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 8
70% more capital invested
Capital invested by funds: $375M → $639M (+$264M)
52% more funds holding
Funds holding: 48 → 73 (+25)
18.13% more ownership
Funds ownership: 33.83% → 51.96% (+18%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$66.6M |
| 2 |
BlackRock
New York
|
+$38.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$23.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$23.4M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$7.45M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.8M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.66M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$1.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Norges Bank
Oslo,
Norway
| – | -$1.66M | -75,000 | Closed |
|
|
MIM
77
MetLife Investment Management
Whippany,
New Jersey
| – | -$126K | -5,716 | Closed |
|
78
DZ Bank
Frankfurt Am Main,
Germany
| – | -$93K | -4,208 | Closed |
|
|
MLICM
79
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$88.9K | -4,020 | Closed |
|
|
SO
80
STRS Ohio
Columbus,
Ohio
| – | -$68K | -3,100 | Closed |
|
|
TRCT
81
Tower Research Capital (TRC)
New York
| – | -$9K | -405 | Closed |
|
APLS Hedge Fund Activity: Q2 2018 in Review
73 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2018, worth a combined $639M — up 70% from $375M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new APLS positions and 8 closed out — a net gain of 25 holders — while 33 added to existing stakes and 4 trimmed.
The largest buyer was Hillhouse Investment Management, adding an estimated $66.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $23.4M sold.
- 73 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2018, up from 48 in Q1 2018.
- Funds reported $639M of Apellis Pharmaceuticals stock for Q2 2018, up 70% quarter-over-quarter.
- 33 funds opened new Apellis Pharmaceuticals positions in Q2 2018 and 8 closed out, a net change of +25 holders.
- The largest Apellis Pharmaceuticals buyer in Q2 2018 was Hillhouse Investment Management, an estimated $66.6M added.
- The largest Apellis Pharmaceuticals seller in Q2 2018 was EcoR1 Capital, an estimated $23.4M sold.
Based on aggregated 13F filings for Q2 2018.